Document Detail

Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years by Nolvadex Adjuvant Trial Organisation.
MedLine Citation:
PMID:  2858709     Owner:  NLM     Status:  MEDLINE    
A randomised controlled trial of tamoxifen as a single adjuvant agent after mastectomy for early breast cancer, reported on at an average follow-up of almost 2 years in 1983, has now been followed up to a maximum of 6 years. 1285 patients aged 75 or less were entered into the trial. Premenopausal women with positive axillary nodes and postmenopausal women with both positive and negative axillary nodes were randomised to receive either tamoxifen 10 mg twice daily for two years or to the untreated control group with systemic therapy reserved until the time of relapse. 46% of the trial population had primary tumour specimens assayed for oestradiol receptor (ER) content. There has been a highly significant prolongation of the disease-free interval in the tamoxifen-treated group followed by a highly significant reduction in death rate, with 45 (34%) fewer deaths observed in the treated group than in the control group. This benefit appeared to be independent of menopausal, nodal, or ER status.
Related Documents :
24857189 - Plasma fibrinogen level on admission to the intensive care unit is a powerful predictor...
23453079 - Does prostate morphology affect outcomes after holmium laser enucleation?
24886499 - Good performances but short lasting efficacy of actellic 50 ec indoor residual spraying...
23562809 - Gait patterns differ between acl-reconstructed athletes who pass return-to-sport criter...
7146149 - The response of keloid scars to cryosurgery.
20480799 - Use of a collagen-glycosaminoglycan copolymer (integra) in combination with adjuvant tr...
19597879 - Stabilized infective endocarditis and altered heparin responsiveness during cardiopulmo...
22901569 - Cyclosporine a for refractory interstitial cystitis/bladder pain syndrome: experience o...
1860289 - Malarial chemoprophylaxis and the healing of periodontal lesions.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Lancet     Volume:  1     ISSN:  0140-6736     ISO Abbreviation:  Lancet     Publication Date:  1985 Apr 
Date Detail:
Created Date:  1985-05-17     Completed Date:  1985-05-17     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  2985213R     Medline TA:  Lancet     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  836-40     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Breast Neoplasms / analysis,  drug therapy*
Clinical Trials as Topic
Follow-Up Studies
Middle Aged
Random Allocation
Receptors, Estradiol / analysis
Tamoxifen / administration & dosage,  adverse effects,  therapeutic use*
Reg. No./Substance:
0/Receptors, Estradiol; 10540-29-1/Tamoxifen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Treatment of active rheumatoid arthritis with slow intravenous injections of thymopentin. A double-b...
Next Document:  Prevention of pre-eclampsia by early antiplatelet therapy.